Medical marijuana initiatives : are they justified? How successful are they likely to be?
The principal constituent of cannabis, Delta(9)-tetrahydrocannabinol (THC), is moderately effective in treating nausea and vomiting, appetite loss, and acute and chronic pain. Oral THC (dronabinol) and the synthetic cannabinoid, nabilone, have been registered for medical use in the US and UK, but they have not been widely used because patients find it difficult to titrate doses of these drugs. Advocates for the medical use of cannabis argue that patients should be allowed to smoke cannabis to relieve these above-mentioned symptoms. Some US state governments have legislated to allow the medical prescription of cannabis, but the US federal government has tried to prevent patients from obtaining cannabis and threatened physicians who prescribe it with criminal prosecution or loss of their licence to practise. In the UK and Australia, committees of inquiry have recommended medical prescription (UK) and exemption from criminal prosecution (New South Wales, Australia), but governments have not accepted these recommendations. The Canadian government allows an exemption from criminal prosecution to patients with specified medical conditions. It has recently legislated to provide cannabis on medical prescription to registered patients, but this scheme so far has not been implemented. Some advocates argue that legalising cannabis is the only way to ensure that patients can use it for medical purposes. However, this would be contrary to international drug control treaties and is electorally unpopular. The best prospects for the medical use of cannabinoids lie in finding ways to deliver THC that do not involve smoking and in developing synthetic cannabinoids that produce therapeutic effects with a minimum of psychoactive effects. While awaiting these developments, patients with specified medical conditions could be given exemptions from criminal prosecution to grow cannabis for their own use, at their own risk.
Hall
Wayne
W
Office of Public Policy and Ethics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia. w.hall@imb.uq.edu.au
Degenhardt
Louisa
L
D000932:Antiemetics / Q000627:therapeutic use; D002188:Cannabis / Q000737:chemistry*; D019247:HIV Wasting Syndrome / Q000188:drug therapy; D006801:Humans; D007880:Legislation, Drug; D009325:Nausea / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use; D016896:Treatment Outcome; D014839:Vomiting / Q000188:drug therapy
D000932:Antiemetics; D028321:Plant Preparations